SSI Strategy, a life sciences consultancy, agreed to acquire NDA Group, a regulatory affairs and drug development consultancy company. Financial terms were not disclosed. “NDA Group is regarded as the premier regulatory consultancy for Life Sciences companies across the US and Europe, and we’re delighted to build upon our longstanding partnership with this combination,” Doug Locke, SSI Strategy Chief Executive Officer.